EpCAM‐Targeted Erlotinib Delivery: Enhancing Nasopharyngeal Carcinoma Treatment With Polyethylene Glycol‐Coated Graphene Oxide

Documenti analoghi

• Characterizing and Targeting of BCL‐2 Family Members in Nasopharyngeal Carcinoma
  di: A. A. Thai, et al.
  Pubblicazione: (2024)
• Impact of Clinical Surveillance on Outcomes of Locally Recurrent Nasopharyngeal Carcinoma
  di: Tsinrong Lee, et al.
  Pubblicazione: (2025)
• Current Trends in the Management of Recurrent Nasopharyngeal Carcinoma
  di: Vivek C. Pandrangi, et al.
  Pubblicazione: (2025)
• Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
  di: Aarti Bhatia, et al.
  Pubblicazione: (2025)
• Endoscopic Nasopharyngectomy Alone for Pediatric Stage I Nasopharyngeal Carcinoma: A Case Report
  di: Jiong‐Lin Liang, et al.
  Pubblicazione: (2025)